J&J scraps India COVID-19 vaccine trial, aims to accelerate availability - ET

Reuters2021-06-29

BENGALURU, June 29 (Reuters) - Johnson & Johnson will not be undertaking local trials for its single-shot COVID-19 vaccine in India and is looking at ways to accelerate its availability in the country, the Economic Times reported on Tuesday, citing a company spokesperson.

J&J said in April it was in talks with India's government to begin a bridging clinical study of its Janssen COVID-19 vaccine candidate in the country.

In late May, India said it would scrap local trials altogether for "well-established" vaccines manufactured in other countries.

The U.S.-based drugmaker is exploring how to accelerate the availability of its vaccine in India, the Economic Times report said. ()

Over 41 million COVID-19 vaccine doses were administered across India last week, with pandemic-induced restrictions being eased further.

Experts have said widespread vaccination remains one of the best tools to avoid the kind of devastation India saw during its second wave of the pandemic.

J&J did not immediately respond to a Reuters request for comment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

CKRI
2021-06-29
CKRI
Much needed!
newbieb
2021-06-29
newbieb
Hi
beebeeyan
2021-06-29
beebeeyan
fb up
zhaooa
2021-06-29
zhaooa
hi
Butt3rc00ki3
2021-06-29
Butt3rc00ki3
Like
slice
2021-06-29
slice
Hi

Leave a comment

25

49

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2147859758?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-06-29 13:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2147859758","market":"us","top_or_hot":-1,"title":"J&J scraps India COVID-19 vaccine trial, aims to accelerate availability - ET","media":"Reuters","content":"<p>BENGALURU, June 29 (Reuters) - Johnson &amp; Johnson will not be undertaking local trials for its single-shot COVID-19 vaccine in India and is looking at ways to accelerate its availability in the country, the Economic Times reported on Tuesday, citing a company spokesperson.</p>\n<p>J&amp;J said in April it was in talks with India's government to begin a bridging clinical study of its Janssen COVID-19 vaccine candidate in the country.</p>\n<p>In late May, India said it would scrap local trials altogether for \"well-established\" vaccines manufactured in other countries.</p>\n<p>The U.S.-based drugmaker is exploring how to accelerate the availability of its vaccine in India, the Economic Times report said. ()</p>\n<p>Over 41 million COVID-19 vaccine doses were administered across India last week, with pandemic-induced restrictions being eased further.</p>\n<p>Experts have said widespread vaccination remains <a href=\"https://laohu8.com/S/AONE\">one</a> of the best tools to avoid the kind of devastation India saw during its second wave of the pandemic.</p>\n<p>J&amp;J did not immediately respond to a Reuters request for comment.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>J&J scraps India COVID-19 vaccine trial, aims to accelerate availability - ET</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJ&J scraps India COVID-19 vaccine trial, aims to accelerate availability - ET\n</h2>\n\n<h4 class=\"meta\">\n\n2021-06-29 13:59 北京时间&nbsp;&nbsp;&nbsp;<strong>Reuters</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BENGALURU, June 29 (Reuters) - Johnson & Johnson will not be undertaking local trials for its single-shot COVID-19 vaccine in India and is looking at ways to accelerate its availability in the country...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JNJ","symbol_name":"强生","start_time":0,"source_url":null,"article_id":"2147859758","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2147859758","pubTimestamp":1624946364,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"BENGALURU, June 29 (Reuters) - Johnson & Johnson will not be undertaking local trials for its single","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"JNJ":"强生"},"translate_title":"J&J废弃印度新冠肺炎疫苗试验，旨在加快可用性-ET","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":0.9},"content_text":"BENGALURU, June 29 (Reuters) - Johnson & Johnson will not be undertaking local trials for its single-shot COVID-19 vaccine in India and is looking at ways to accelerate its availability in the country, the Economic Times reported on Tuesday, citing a company spokesperson.\nJ&J said in April it was in talks with India's government to begin a bridging clinical study of its Janssen COVID-19 vaccine candidate in the country.\nIn late May, India said it would scrap local trials altogether for \"well-established\" vaccines manufactured in other countries.\nThe U.S.-based drugmaker is exploring how to accelerate the availability of its vaccine in India, the Economic Times report said. ()\nOver 41 million COVID-19 vaccine doses were administered across India last week, with pandemic-induced restrictions being eased further.\nExperts have said widespread vaccination remains one of the best tools to avoid the kind of devastation India saw during its second wave of the pandemic.\nJ&J did not immediately respond to a Reuters request for comment.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":159664707,"gmtCreate":1624964167409,"gmtModify":1703848928726,"author":{"id":"3578398190985905","authorId":"3578398190985905","name":"CKRI","avatar":"https://static.tigerbbs.com/46ea6437d16414ca8a956e66caf2c956","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3578398190985905","idStr":"3578398190985905"},"htmlText":"Much needed!","listText":"Much needed!","text":"Much needed!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159664707","repostId":2147859758,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":159121479,"gmtCreate":1624949913991,"gmtModify":1703848655795,"author":{"id":"4087907213563300","authorId":"4087907213563300","name":"newbieb","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4087907213563300","idStr":"4087907213563300"},"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159121479","repostId":2147859758,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":159167517,"gmtCreate":1624949530739,"gmtModify":1703848650253,"author":{"id":"3581331692871918","authorId":"3581331692871918","name":"beebeeyan","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3581331692871918","idStr":"3581331692871918"},"htmlText":"fb up","listText":"fb up","text":"fb up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159167517","repostId":2147859758,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":159185668,"gmtCreate":1624948600554,"gmtModify":1703848638752,"author":{"id":"3573730312795304","authorId":"3573730312795304","name":"zhaooa","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"hat":"https://static.tigerbbs.com/f84d87792f02cf78e80ee34979fd31e5","crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"3573730312795304","idStr":"3573730312795304"},"htmlText":"hi","listText":"hi","text":"hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159185668","repostId":2147859758,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":159182769,"gmtCreate":1624948557251,"gmtModify":1703848632434,"author":{"id":"3581548481060535","authorId":"3581548481060535","name":"Butt3rc00ki3","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3581548481060535","idStr":"3581548481060535"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159182769","repostId":2147859758,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":159182029,"gmtCreate":1624948494861,"gmtModify":1703848630976,"author":{"id":"3562131191035418","authorId":"3562131191035418","name":"slice","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3562131191035418","idStr":"3562131191035418"},"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159182029","repostId":2147859758,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":49,"commentSize":25,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2147859758"}